Study: No benefit from intermittent therapy in prostate cancer

04/4/2013 | HealthDay News

Patients with metastatic prostate cancer who received intermittent androgen deprivation therapy had a 10% greater risk of mortality than those who got continuous hormone treatment, according to a study published in the New England Journal of Medicine. Researchers tracked more than 1,500 patients and found average survival rates of 5.8 years for the continuous therapy group and 5.1 years for the intermittent treatment group. Men who received intermittent treatment initially reported better quality of life and mental health, but those gains were lost by the end of the study.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ